Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II

Podobne zapisy

• Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II
  od: Namas, Rajaie, i wsp.
  Wydane: (2018)
• Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II
  od: Volkmann, Elizabeth R., i wsp.
  Wydane: (2017)
• Cyclophosphamide for Systemic Sclerosis-Related Interstitial Lung Disease: A Comparison of Scleroderma Lung Studies I and II
  od: Volkmann, Elizabeth R., i wsp.
  Wydane: (2019)
• Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II
  od: Goldin, Jonathan G., i wsp.
  Wydane: (2018)
• Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo: Findings From the Scleroderma Lung Study
  od: Goldin, Jonathan, i wsp.
  Wydane: (2009)